UConn Health Researcher Receives Patent for Cancer-fighting Antibody – UConn Today

UConn Health professor of cell biology Kevin Claffey recently received a patent for a novel antibody designed to target an important cancer cell membrane protein.

Heat Shock Protein 90 (Hsp90) plays an important role in cancer cell proliferation. Hsp90 is a chaperone protein that helps other proteins fold properly and stabilizes many proteins, including those required for tumor growth. Hsp90 is integral to the survival of the cells it assists. Cancer cells are more dependent on elevated levels of Hsp90 than healthy, non-cancerous cells making it an attractive target for therapies.

Claffey has derived antibodies produced in breast cancer patients lymph nodes that specifically target this protein on cancer cell membranes. These biological antibodies directly and specifically target only tumor cells rather than all cells that have Hsp90 on their surface.

The antibody HCAb2, which occurs naturally in cancer patients, specifically targets cancer cells Hsp90 proteins. Claffey used this biological antibody as a template to develop a synthetic version which could be a potent treatment for multiple kinds of cancer.

Other antibodies used in cancer treatment target signally receptors on the surface of tumor cells. However, these receptors are also essential for normal cell functioning leading to a host of adverse side effects.

While there have been many attempts to develop a drug that targets Hsp90, this is the first time a researcher has found antibodies that bind specifically to the tumor and the selectively induced stress protein.

Claffeys molecule has demonstrated the potential to inhibit Hsp90 selectively for melanoma, bladder and ovarian cancer types.

Related to this technology, Claffey has developed a platform for cancer antigen discovery that applies a unique biochemistry and molecular biology technology. This platform recovers antibodies from patients and identifies the cancer proteins that their own immune system has targeted as abnormal. This platform-based method can therefore isolate and identify tumor-specific antigens as well as patient-derived single domain antibodies specific to those antigens. By using this platform, Claffey found the HSP90-beta isoform that is inadvertently present on the extracellular face of highly metabolic cancer cells, and thus presents a cancer-selective target for antibodies which can then be incorporated into engineered T-cell therapies, such as CAR-T cells.

The platform was validated using materials available to the PI from late stage metastatic breast cancer patients; breast cancer patients; melanoma patients; and breast cancer patient sentinel lymph nodes. For more information about the technology and partnering opportunities, contact Amit Kumar (a.kumar@uconn.edu).

Claffey holds a Ph.D. in biochemistry and molecular biology from Boston University. He completed his postdoctoral training at the Dana-Faber Cancer Institute and Harvard Medical School Department of Biological Chemistry and Molecular Pharmacology. His research focuses on pre-clinical models of breast cancer, targeting angiogenesis and VEGF-dependent mechanisms.

Follow UConn Research on Twitter & LinkedIn.

Excerpt from:
UConn Health Researcher Receives Patent for Cancer-fighting Antibody - UConn Today

A systems-level approach to understanding the immunology of COVID-19 in adults and children on SelectScience – SelectScience

This webinar will present recent studies from Dr. Petter Brodin's group at Karolinska Institute in Stockholm that provide important new insights into the immune system responses to SARS-CoV-2 infection. These studies took a systems-level approach to analyze both the cellular and protein components involved, using methodologies including mass cytometry, flow cytometry and high-multiplex proteomics.

A longitudinal study of severe COVID-19 patients identified distinct patterns of immune cell coregulation in four different stages of the disease and demonstrated a shared trajectory of immunological recovery that may provide future biomarkers of disease progression. In an investigation of Multisystem Inflammatory Syndrome in Children (MIS-C), a relatively rare complication of SARS-CoV-2 infection in children, important differences in inflammatory response were seen between MIS-C and severe COVID-19 in adults. Moreover, while some similarities were observed between inflammatory responses in MIS-C and Kawasaki disease, important differences were also apparent, particularly in the T-cell subsets involved.

Key Learning Objectives

Who Should Attend

Certificate of attendance

All webinar participants can download a certificate of attendance for continuing education purposes from the webinar auditoriums resources section.

Read the original:
A systems-level approach to understanding the immunology of COVID-19 in adults and children on SelectScience - SelectScience

Eck Institute members host webinar to combat COVID-19 myths, misinformation – Observer Online

Heidi Beidinger-Burnett and Mary Ann McDowell, both of the University of Notre Dames Eck Institute for Global health, are taking on misinformation and misunderstanding of the coronavirus pandemic with their new webinar series called Consider This! Simplifying the COVID-19 Conversation.

Beidinger-Burnett serves as the director of the Eck Institute for Global Health and president of the St. Joseph County Board of Health. McDowell, an associate professor of biological sciences and a member of the Eck Institute for Global Health, is an expert in infectious disease and immunology. Through their combined backgrounds, the two doctors said they hope to increase the scientific literacy of the Notre Dame community regarding the virus and public health policies.

We were finding misconceptions or myths about the science and public health of COVID-19, Beidinger-Burnett said. The idea for us is to simplify the conversation for people to be more comfortable with the terminology and to be more in control of the information.

Consider This! aims to cut through the growing distrust in the media and correct the common myths of the virus so that the Notre Dame and St. Joseph County communities can better protect themselves.

McDowell said the myths that concern her the most are the beliefs that herd immunity should be embraced, that the coronavirus pandemic is over and that a widely available vaccine will arrive prior to election day or early next year.

You have to model the behavior. This is leadership 101, Burnett-Beidinger said. We have a president who was saying, We dont need a mask, oh, its not masculine, I dont need it. Remember, he made fun of Joe Biden. Well, Joe Biden was adhering to what CDC and all the others were telling us that we needed to be doing to safeguard ourselves. So that void in leadership has significantly contributed to the myths and the rumors that have been spread about this, and the distrust in the science.

The webinar series will be conversational in tone while also drawing upon the expertise of over 15 specialists in immunology, public health and public policy.

I think that we have a science literacy problem all over the world but [also] in the United States, McDowell said. And you know, I would say thats really a fault of the scientists, in some ways, because we havent done a good job of communicating our work and making it accessible.

The two co-hosts want their series to be as accessible and conversational as possible to students and community members. They hope this approach can alleviate fears and increase cooperation with community guidelines set by teams of public health experts. McDowell also encouraged students to contact [emailprotected] with any questions or myths they want the series to address.

Monday night, Consider This! went live for the first time. The two co-hosts began by discussing the current virus statistics in St. Joseph County. They continued on to a segment titled Rumor Has It, in which they confronted herd immunity parties on college campuses and the dangers they pose to young adults.

The episode concluded with a conversation with University Provost Marie Lynn Miranda. Miranda has a background in the field of childrens environmental health and, while provost, teaches in the applied and computational mathematics and statistics department at Notre Dame.

The inaugural episode emphasized one thing: COVID-19 is still around and something that communities will have to learn to live with. Next week, Beidinger-Burnett and McDowell will talk with Brian Baker, department head in the department of chemistry and biochemistry, and Jeffery Schorey, a professor in the department of biological sciences.

Registration for the webinars can be found under the Eck Institute for Global Healths website.

See original here:
Eck Institute members host webinar to combat COVID-19 myths, misinformation - Observer Online

Skyhawk Therapeutics Expands Leadership Team with Chief Medical Officer and Head of Chemistry, and adds to its Scientific Advisory Board – BioSpace

Joseph Duffy PhD brings 20+ years of small molecule discovery chemistry and operations to his role as SVP Chemistry of Skyhawk Therapeutics, Elliot Ehrich MD brings 20+ years of clinical development for novel pharmaceuticals to his role as Chief Medical Officer of Skyhawk Therapeutics,and Rob Hershberg MD-PhD with 25+ years of biotech and pharma experience has joined Skyhawk's Scientific Advisory Board.

WALTHAM, Mass., Oct. 5, 2020 /PRNewswire/ -- Skyhawk Therapeutics today announced that Dr. Elliot Ehrich has joined the Company as Chief Medical Officer and Dr. Joseph Duffy has joined as Senior Vice President of Chemistry. The Company also strengthened its Scientific Advisory Board with the addition of Dr. Rob Hershberg.

"We are delighted that Joe and Elliot have come on board at Skyhawk," said Bill Haney, co-founder and CEO of Skyhawk Therapeutics. "Their combined scientific and clinical accomplishments will be invaluable in shepherding our novel RNA-targeting small molecule drug candidates successfully into the clinic. We are also excited to welcome Rob to our Scientific Advisory Board. His clinical and scientific insight and deep experience as a drug developer will be a tremendous addition to Skyhawk."

Elliot Ehrich, MD most recently served as a Venture Partner at 5AM Ventures and Chief Medical Officer (CMO) at Expansion Therapeutics, a 5AM Ventures portfolio company. Previously, Dr. Ehrich spent 17 years at Alkermes ultimately as Executive Vice President of R&D and CMO. At Alkermes he led the development and successful FDA registration of multiple new medicines. Dr. Ehrich has also worked in clinical pharmacology and clinical research at Merck &Co, Inc..

Dr. Ehrich received a BA in biochemistry from Princeton University and an MD from Columbia University. He completed a residency in internal medicine and a fellowship in immunology and rheumatology at Stanford University Medical School followed by postdoctoral research the Department of Microbiology and Immunology.

Over the past four years, Joseph Duffy PhD, served as Executive Director of Discovery Chemistry atMerckResearch Laboratories in Rahway and Kenilworth, New Jersey, where he oversaw multiple preclinical drug discovery teams. Dr. Duffy's contributions over 24 years at Merck included all phases of drug discovery, from lead identification through clinical phase candidate development. He directed successful lead optimization efforts for multiple indications, resulting in clinical candidates and Investigational New Drug (IND) applications from both internal projects and international collaborative research with biotech organizations. Dr. Duffy received his B.Sc. in Chemistry from Kent State University and his Ph.D. from Harvard University.

Rob Hershberg MD-PhD began his career as an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women's Hospital in Boston. Later, Dr. Hershberg co-founded VentiRx Pharmaceuticals and, as President and Chief Executive Officer, led the company through its transformational partnership with Celgene. Dr. Hershberg joined Celgene in 2014 to lead their efforts in Immuno-Oncology, was promoted to Chief Scientific Officer in 2016, and was subsequently Executive Vice President and Head of Business Development & Global Alliances and served as a member of the Executive Committee until the acquisition of Celgene by Bristol-Myers Squibb in 2019. Rob is currently a Venture Partner on the Frazier Life Sciences team. He completed his undergraduate and medical degrees at the University of California, Los Angeles and received his Ph.D. at the Salk Institute for Biological Studies.

Dr Hershberg joins Skyhawk's distinguished Scientific Advisory Board which includes:

Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTARTM (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.

For more information visit: http://www.skyhawktx.com, https://twitter.com/Skyhawk_Tx, https://www.linkedin.com/company/skyhawk-therapeutics/

SKYHAWK MEDIA CONTACT:Anne Deconinckanne@skyhawktx.com

View original content:http://www.prnewswire.com/news-releases/skyhawk-therapeutics-expands-leadership-team-with-chief-medical-officer-and-head-of-chemistry-and-adds-to-its-scientific-advisory-board-301145628.html

SOURCE Skyhawk Therapeutics

Read the original post:
Skyhawk Therapeutics Expands Leadership Team with Chief Medical Officer and Head of Chemistry, and adds to its Scientific Advisory Board - BioSpace

CSU scientists work to curb the spread of COVID-19 with targeted testing – Source

Susan DeLong, associate professor of Civil and Environmental Engineering, and students Nicholas Mohammed and Thomas Anderson, sample wastewater that will be tested by Professor Carol Wilusz lab on campus.

After move-in week, CSU pivoted its efforts to wastewater surveillance from 17 locations tied to residence halls on campus. Coronavirus is shed in the feces before it can be identified from the standard swab test and days before a person would develop symptoms.

Two CSU professors, Carol Wilusz from the Department of Microbiology, Immunology, and Pathology and Susan DeLong from the Department of Civil and Environmental Engineering, developed a method to collect wastewater in a 24-hour composite sample and return results for SARS-CoV-2 30 hours later.

Wastewater testing is supplemental to and helps drive nasal-swab testing, since it is used to help identify target populations to test. Targeted surveillance in helping to reduce the spread of the virus also can help reduce the overall cost of testing. The process used for each COVID-19 nasal swab costs $100 and includes collection and analysis by an independent company.

When you have limited funds and limited access to tests, (wastewater monitoring) is one way that you can make the most of the funding that you have, said Wilusz.

When a wastewater sample shows a spike in viral counts, the university focuses nasal-swab testing efforts on the people in those areas and its working, according to Wilusz.

There was a bit of a signal from one residence hall at the beginning of September, she said. It wasnt a huge one, and (through individual testing) they found six people in there that had it.

Follow this link:
CSU scientists work to curb the spread of COVID-19 with targeted testing - Source

Ludwig Study Finds a Common Nutritional Supplement Might Boost the Effects of Cancer Immunotherapy – Newswise

Newswise OCTOBER 5, 2020, NEW YORK A Ludwig Cancer Research study has uncovered a mechanism by which the tumors harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response. Reported in Nature Immunology, the study describes how a variety of stressors prevalent in the tumor microenvironment disrupt the power generators, or mitochondria, of tumor-infiltrating T lymphocytes (TILs), pushing them into a permanently sluggish state known as terminal exhaustion.

The study, led by Ludwig Lausanne Associate Member Ping-Chih Ho, also found that a widely available nutritional supplementnicotinamide riboside (NR)helps TILs overcome the mitochondrial dysfunction and preserves their ability to attack tumors in mouse models of melanoma and colon cancer.

TILs often have a high affinity for antigens expressed by cancer cells, says Ho. This means that, in principle, they should attack cancer cells vigorously. But we often dont see that. People have always wondered why because it suggests that the best soldiers of the immune system are vulnerable when they enter the battlefield of the tumor. Our study provides a mechanistic understanding of why this happens and suggests a possible strategy for preventing the effect that can be quickly evaluated in clinical trials.

The inner recesses of tumors are often starved of oxygen and essential nutrients, such as the sugar glucose. Cells in these stressful conditions adjust their metabolic processes to compensatefor example, by making more mitochondria and burning their fat reserves for energy.

In tumors, prolonged stimulation by cancer antigens is known to push TILs into an exhausted state marked by the expression of PD-1a signaling protein that suppresses T cell responses and is targeted by existing checkpoint blockade immunotherapies. If sustained, such exhaustion can become permanent, persisting even when the stimulus of cancer antigens is removed.

Ho and his colleagues found that exhausted TILs are packed with damagedor depolarizedmitochondria. Like old batteries, depolarized mitochondria essentially lack the voltage the organelles require to generate energy.

Our functional analysis revealed that those T cells with the most depolarized mitochondria behaved most like terminally exhausted T cells, said Ho.

Ho and colleagues show that the accumulation of depolarized mitochondria is caused primarily by the TILs inability to remove and digest damaged ones through a process known as mitophagy. The TILs can still make new mitochondria but, because they dont remove the old ones, they lack the space to accommodate the new ones, said Ho.

The genomes of these TILs are also reprogrammed by epigenetic modificationschemical groups added to DNA and its protein packagingto induce patterns of gene expression associated with terminal exhaustion.

The researchers found that the breakdown in mitophagy stems from a convergence of factors: chronic stimulation by cancer antigens, PD-1 signaling and the metabolic stress of nutrient and oxygen deprivation. They also show that the epigenetic reprograming that fixes TILs in a terminally exhausted state is a consequence, not a cause, of the mitochondrial dysfunction.

Related work done by other researchersincluding co-authors in the current study, Ludwig Lausanne Investigator Nicola Vannini and Ludwig Lausanne Branch Director George Coukoshas shown that NR, a chemical analogue of vitamin B3, can boost mitophagy and improve mitochondrial fitness in a variety of other cell types.

With this in mind, the researchers explored whether NR might also prevent TILs from committing to terminal exhaustion. Their cell culture experiments showed that the supplement improved the mitochondrial fitness and function of T cells grown under stressors resembling those of the tumor microenvironment.

More notably, dietary supplementation with NR stimulated the anti-tumor activity of TILs in a mouse model of skin cancer and colon cancer. When combined with anti-PD-1 and another type of checkpoint blockade, anti-CTLA-4 immunotherapy, it significantly inhibited the growth of tumors in the mice.

We have shown that we may be able to use a nutritional approach to improve checkpoint blockade immunotherapy for cancer, said Ho.

He and his colleagues are now exploring the signals from depolarized mitochondria that epigenetically reprogram TILs for terminal exhaustioninformation that could be more generally applied to improve cancer immunotherapy.

Ho is an Associate Member of the Lausanne Branch of the Ludwig Institute for Cancer Research and an Associate Professor at the University of Lausanne.

This study was supported by Ludwig Cancer Research, the Swiss National Science Foundation, the Swiss Institute for Experimental Cancer Research, European Research Council, the Kristian Gerhard Jebsen Foundation, the Austrian Science Fund, the Austrian Academy of Sciences, the European Research Council, the Swiss Ministry of Science and Technology, the National Health Research Institute in Taiwan and the Swiss Cancer League.

About Ludwig Cancer Research

Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for nearly 50 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit http://www.ludwigcancerresearch.org.

See more here:
Ludwig Study Finds a Common Nutritional Supplement Might Boost the Effects of Cancer Immunotherapy - Newswise

Scientists map genetic networks that control the biology of regulatory T cells – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Oct 1 2020

Unlike most T cells, which launch immune responses against foreign molecules, regulatory T cells are the peacekeepers of the human immune system, damping down inflammatory reactions when they're not needed. Now, researchers at Gladstone Institutes, in collaboration with scientists at UC San Francisco (UCSF) and the Technical University of Munich (TUM), have mapped out the networks of genes that help differentiate regulatory T cells from other T cells. Their findings could lead to immune therapies that strengthen or weaken the function of regulatory T cells.

Piecing together the genetic networks that control the biology of regulatory T cells is a first step toward finding drug targets that change the function of these cells to treat cancer and autoimmune diseases."

Alex Marson, MD, PhD, senior author of the study, Director of the Gladstone-UCSF Institute of Genomic Immunology

All T cells, named because they develop in the thymus gland, have similar receptors on their surfaces and play a role in the immune responses that destroy viruses, bacteria, and some cancer cells. But regulatory T cells have a distinct function, acting as a brake to suppress other T cells so that immune reactions don't go overboard. Studies in mice have suggested that increasing the number of regulatory T cells--and therefore putting stronger "brakes" on the immune system--might help subdue symptoms of autoimmune diseases. On the other hand, blocking regulatory T cells, or lifting these molecular brakes, is suspected to help the immune system better fight cancer.

Therapies that boost populations of regulatory T cells--by removing the cells from patients' bodies, expanding them, and infusing them back in--are already being tested in people with autoimmune disease, including type 1 diabetes, and organ transplant recipients. So far, however, such treatments generally haven't involved actually altering the function of the immune cells.

"Most of our previous knowledge about regulatory T cells is from mouse models," says Kathrin Schumann, a co-first and co-corresponding author of the paper and former UCSF postdoctoral fellow, now an assistant professor at the Technical University of Munich. "We wanted to genetically dissect human regulatory T cells to better understand how they're wired and how we can manipulate them. Once we understand the functions of each gene, we can precisely edit cells to treat disease."

In the new study, published in the journal Nature Immunology, Marson, Schumann, and their collaborators used CRISPR-based gene-editing technology to alter regulatory T cells, selectively removing any of 40 different transcription factors. The 40 transcription factors--master genes that control the activation of many other genes--were chosen because previously published data had already hinted that they might perform specific functions in the regulatory cells compared to other T cells.

The researchers then focused on the 10 transcription factors that had the strongest effect in this initial screen, and looked across tens of thousands of genes to see which ones were turned on or off in the altered cells. In all, they performed this analysis on 54,424 individual regulatory T cells.

By analyzing the subsets of genes activated or silenced by these 10 original transcription factors, the team put together vast networks of genetic programs involved in the biology of regulatory T cells. Among the most surprising results, the study revealed that the little-studied transcription factor HIVEP2 has a strong effect on regulatory T cell function. In follow-up studies in mice, the scientists found that removing the HIVEP2 gene reduced the ability of the regulatory T cells to quell inflammation.

"This was a significant hit," said Sid Raju, a co-first author of the paper and former UCSF computational biologist who is now a graduate student at the Broad Institute of MIT and Harvard. "This gene had really never been implicated in regulatory T cell biology before."

The team also says their study acts as a proof-of-principle for how powerful the combination of CRISPR gene editing and the analysis of individually edited cells can be in studying the genetics of human biology and human disease.

"Now, we can theoretically take any specialized cell from the body and start removing individual genes and study the consequences on the cells in much finer detail than ever before," says Marson. "This really opens up human cells removed from the body as a tractable experimental system."

Source:

Journal reference:

Schumann, K., et al. (2020) Functional CRISPR dissection of gene networks controlling human regulatory T cell identity. Nature Immunology. doi.org/10.1038/s41590-020-0784-4.

Read more from the original source:
Scientists map genetic networks that control the biology of regulatory T cells - News-Medical.Net

Excerpt The Infinite Complexity of Cells – Discovery Institute

Image: Radiolarian shells, by Ernst Haeckel / Public domain.

Editors note: We are pleased to offer this excerpt from Dr. Dentons new book, The Miracle of the Cell.

In terms of compressed complexity, cells are without peer in the material world, actualized or imagined. And there is likely far more complexity still to uncover. Even as recently as 1913, when Lawrence Henderson composed his classic The Fitness of the Environment, the cell was a black box, its actual molecular complexity a mysterious unknown. Only as the veil began to lift with the mid-century molecular biological revolution did science begin to glimpse the sophistication of these extraordinary pieces of matter. Subsequently, every decade of research has revealed further depths of complexity. The discovery of ever more intricate structures and systems with each increase in knowledge including vastly complex DNA topologies and a vast and growing inventory of mini-RNA regulator molecules tells us there is probably much more to uncover. What we glimpse now may be only a tiny fraction of what remains to be discovered.

As Erica Hayden confessed in the journal Nature, As sequencing and other new technologies spew forth data, the complexity unearthed by cell biology has seemed to grow by orders of magnitude. Delving into it has been like zooming into a Mandelbrot set that reveals ever more intricate patterns as one peers closer at its boundary.

There is much more to discover about the cell, but even from our current limited knowledge of its depths it is clear that this tiny unit of compact, adaptive sophistication constitutes something like a third infinity. Where the cosmos feels infinitely large and the atomic realm infinitely small, the cell feels infinitely complex.

But cells are not just complex beyond any sensible measure and beyond any other conceivable material form. They appear in so many ways supremely fit to fulfill their role as the basic unit of biological life. One element of this fitness is manifest in their incomparable diversity of form. Contrast a neuron with a red blood cell, a skin cell with a liver cell, an amoeboid leucocyte with a muscle cell. Each of these different forms is found in the human body, and many more. Or consider the diversity of ciliate protozoans. From the trumpet-like Stentor to the dashing Paramecium, the universe of ciliate form is absurdly diverse. Or take the radiolarians. Even within this small related group of organisms, the diversity of cell forms is stunning. And yet every member of this fantastic zoo of radiolarian forms is built on exactly the same canonical design.

The unique fitness of the cell to serve as the fundamental unit of life is also manifest in its amazing abilities and the diversity of functions it performs. Even the tiny E. coli, a cylinder-shaped bacterium in the human gut, has spectacular capabilities. Howard Berg has marveled at the versatility and capacities of this minuscule organism, calling its talents legion. He notes that this tiny organism, less than one-millionth of a meter in diameter and two-millionths of a meter long, so small that 20 would fit end-to-end in a single rod cell of the human retina, is nevertheless adept at counting molecules of specific sugars, amino acids, or dipeptides; at integration of similar or dissimilar sensory inputs over space and time; at comparing counts taken over the recent and not so recent past; at triggering an all-or-nothing response; at swimming in a viscous medium even pattern formation.

Cells also move in many diverse ways. E. coli travel by the propeller- like action of the bacterial flagellum. Others do so via the beating action of cilia. Some creep and crawl. Some put out pseudopodia and grasp small objects in their immediate vicinity.

Some cells can survive desiccation for hundreds of years. Cells possess internal clocks and can measure the passage of time. They can sense electrical and magnetic fields, and communicate via chemical and electrical signals. Some can encase themselves in armor-like skins. Some may be able to see; one species of ciliate has a lens able to focus an image on another region of the cytoplasm in effect, an eye. All can replicate themselves with seeming ease, an act far beyond even the most complex human artifact. Some can even reconstruct themselves completely from tiny fractions cut surgically from the cell!

These remarkable specks of organized matter have constructed every multicellular organism on Earth, including the human body, itself a vast collective of as many as 100 million million cells. Cells compose the human brain, making a million connections a minute for nine months during gestation. Cells build blue whales, butterflies, birds, and the giant sequoias of Yosemite. Cells constituted the dinosaurs and all past life ever born on Earth. And through the activities of some of the simplest of their kind, cells gradually terraformed the planet over the past 3,000 million years, generating oxygen via photosynthesis and releasing its energizing powers for all the higher life forms. They are the universal constructor set of life on Earth. In short, they can do almost anything, adopt almost any shape, and obey any order. They appear, in every sense, perfectly adapted to their assigned task of creating a biosphere replete with multicellular organisms like ourselves.

When we observe the goings-on of protozoans in a drop of pond water or the antics of an amoeboid leucocyte in the human blood stream chasing a bacterium, it is hard to resist the feeling that these microscopic life forms are sentient, autonomous beings. This was the case when we had relatively primitive microscopic technology more than one hundred years ago, and it is all the more so today.

It is not just their hunting strategies (seen in a video of a leucocyte chasing its prey, below) that resemble the behaviors of higher organisms.

Another striking example is the courtship rituals of ciliates, rituals that include pre-conjugal mating dances, reciprocal learning, repeated touching of prospective mates, and even deceit and cheating when communicating reproductive fitness to potential mates. One of the founders of behaviorism, Herbert Spencer Jennings, strongly suspected that protozoa were sentient. As he confessed, If Amoeba were a large animal, so as to come within the everyday experience of human beings, its behavior would at once call forth the attribution to it of states of pleasure and pain, of hunger, desire, and the like, on precisely the same basis as we attribute these things to the dog.

Jenningss thoughts were recently echoed by biologist Brian Ford: The microscopic world of the single, living cell mirrors our own in so many ways: cells are essentially autonomous, sentient and ingenious. In the lives of single cells we can perceive the roots of our own intelligence. And as Ford continues, We regard amoebas as simple and crude. Yet many types of amoeba construct glassy shells by picking up sand grains from the mud in which they live. The typical Difflugia shell, for example, is shaped like a vase, and has a remarkable symmetry We just dont know how this single-celled organism builds its shell.

Even if cells are not sentient beings, their accomplishments, their complexity, their diversity of structure and function, remain to astound us. The unique powers of cellswhat Jacques Monod called their demonic catalytic powers and their extraordinary fitness to play their unique role as the building blocks of all life on Earth are a wonder apparent to anyone who gives them even a cursory consideration.

An even greater wonder is the stunning prior fitness in nature that enables the material actualization of the canonical carbon-based cell. This prior fitness is manifest in the unique utility of the properties of a significant number of the atoms in the first half of the periodic table to serve highly specific ends essential for the assembly of the core macromolecular constituents and the physiological functioning of the cell. I call this the unique fitness paradigm.

This prior fitness is manifest also in the extraordinary utility of water to serve as the matrix of the cell, and by chemical processes in the dark vastness of interstellar space that result in the abiotic synthesis of many of the molecular monomers used by the first cells to build their macromolecular constituents. In other words, the demonic fitness of the cell depends on a deeper fitness prefigured into the very fabric of reality. This deeper fitness is inscribed in the laws of nature from the beginning of time, a fitness that reveals the cosmos to be, as Henderson proclaimed, a profoundly biocentric whole.

Visit link:
Excerpt The Infinite Complexity of Cells - Discovery Institute

Open Rank Principal Investigator at Life Sciences Institute job with ZHEJIANG UNIVERSITY | 227718 – Times Higher Education (THE)

Would you like to learn more about moving your academic career to Zhejiang University (ZJU)? If so,registerfor our Careers in China webinar mini-series for a chance to meet representatives fromZJUand discuss the latest opportunities there.

Applications are invited for open rank principal investigator (PI) position at Life Sciences Institute (LSI), Zhejiang University.

Founded in October 2009, LSI is the first special academic zone of Zhejiang University. As a key construction project of Zhejiang University, LSI enjoys autonomy in scientific research, human resources, and budgeting as well as an independent graduate training program. Led by Director Dr. Xin-Hua Feng and Co-Director Dr. Kun-Liang Guan, LSI aims for an internationally recognized institute of biomedical research. We are currently recruiting scientists at all ranks, from Investigator to Senior and Distinguished Investigators, regardless of specific areas of research. Candidates with strong track record in cancer biology, stem cell biology, inflammation biology, chemical biology, structural biology (Cryo EM) and other major areas related to human diseases are particularly encouraged.

LSI has established an interdisciplinary research program, state-of-the-art core facilities, and efficient administrative support, all aiming to support cutting edge biomedical research. LSI also offers generous and internationally competitive packages for incoming PIs, including salary/benefit (400,000 RMB), housing (or housing subsidies), and start-up research support (5,000,000 RMB).

Zhejiang University New Hundred Talents Program

The newly launched New Hundred Talents Program is aimed at attracting outstanding scholars both at home and abroad. To those recruited via this program, the university is to adopt an international academic standard and procedure --- the tenure track system.

The university plans to recruit distinguished scholars from both China and abroad by the Hundred Talents Program. Ample funds are available for this program to ensure that scholars have a favorable academic environment and optimum working and living conditions so that they can be dedicated to academic research and the advancement of their fields.

LSI adopts a tenure-track system and is seeking applications for an open rank position:

To apply, please submit the following materials to:

Contact:Ms. GengTel: +86-0571-88206016E-mail:lsi@zju.edu.cn

Read the original post:
Open Rank Principal Investigator at Life Sciences Institute job with ZHEJIANG UNIVERSITY | 227718 - Times Higher Education (THE)